Release Date: November 2007
Valid Through: November 2008
Credits Available: Physicians - 1.0 AMA PRA Category 1 Credit(s)^TM
Fee: There is no fee for this activity

This CME activity is based on the following:

Updates in the Management of Early Stage Non-Small Cell Lung Cancer (NSCLC) 
Chandra Belani, MD, Penn State Cancer Center, Hershey, PA

Advances in the Management of Advanced NSCLC: Are We Making Progress?
David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN

Malignant Pleural Mesothelioma Updates 
David Jackman, MD, Dana-Farber Cancer Institute, Boston, MA

Advances in the Management of Small-Cell Lung Cancer (SCLC) 
David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN

Chandra Belani, MD

Dr. Belani is internationally renowned for his accomplishments in the area of lung cancer therapeutics and new drug development. His research efforts have led to new treatment paradigms for lung cancer. He has chaired national and international trials testing novel prevention, drug development and treatment strategies for lung cancer. Dr. Belani is currently the Miriam Beckner Professor of Medicine at Penn State College of Medicine and the Deputy Director at the Penn State Cancer Institute, Penn State Milton S. Hershey Medical Center. Dr. Belani interacts closely with other lung cancer experts across the world to develop and identify new therapeutic strategies to improve efficacy of interventions for the prevention and treatment of lung and thoracic malignancies.

David Spigel, MD

Dr. Spigel completed medical school at the University of Tennessee in Memphis after attending college at Tulane University. He completed his internship, residency, and chief residency in Internal Medicine at Indiana University Medical Center in Indianapolis, followed by a fellowship in hematology / oncology at the Dana-Farber Cancer Institute in Boston. He currently holds memberships in the American Society of Clinical Oncology and the American College of Physicians.

David Jackman, MD

Dr. David Jackman is a thoracic oncologist at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, and he is a faculty member at Harvard Medical School in Boston, MA.  His research has focused on the use of targeted agents in thoracic tumors, with an emphasis on determining clinical and molecular predictors of response or resistance.  He is closely involved in numerous clinical trials in lung cancer and malignant pleural mesothelioma.

Learning Objectives

Upon completion of this activity, participants should be able to:

• Consider the clinical impact of emerging therapies on survival and quality of life for NSCLC, SCLC, and mesothelioma.
• Evaluate published data based on study design, the reported results, and authors’ conclusions.
• Consider the reviewed data as it relates to previous, concurrent and future treatment of NSCLC, SCLC, and mesothelioma.
• Consider second and third-line treatment options for lung cancer patients who have developed resistance to current treatment.
• Evaluate resistance and the role of next generation drugs.
• Categorize side effects and safety profiles of emerging therapies for NSCLC, SCLC, and mesothelioma.
  
  

Disclaimer

Notwithstanding any language to the contrary, nothing contained herein constitutes, nor is intended to constitute, an offer, inducement, promise, or contract of any kind. The data contained herein are for informational purposes only and are not represented to be error free. Any links to non-Creative Educational Concepts, Inc. (CEC) information are provided as a courtesy. They are not intended to constitute, nor do they constitute, an endorsement of the linked materials by CEC .

Supporters

This activity is supported by an educational grant provided by Genentech and an educational donation provided by Amgen.